| 【Company Research】WuXi Biologics (2269 HK) – Growth momentum intact |
| 【Company Research】Tencent (700 HK) – Looking into 2H22E recovery |
| 【Company Research】InnoCare Pharma (9969 HK) – A successful commercial year for orelabrutinib |
| 【Company Research】Sunny Optical (2382 HK) – Headwinds to persist into 1H22E; Maintain HOLD |
| 【Company Research】Tongcheng-Elong (780 HK) – Looking beyond 3M22E epidemic |
| 【Company Research】Anta Sports (2020 HK) – A mixed guidance but long-term growth intact |
| 【Company Research】GDS (9698 HK) – Remains committed in tier-one cities resources |
| 【Company Research】GDS (GDS US) – Remains committed in tier-one cities resources |
| 【Company Research】CSPC Pharmaceutical (1093 HK) – Promising early data of COVID-19 mRNA vaccine |
| 【Company Research】Sunny Optical (2382 HK) – 2H21 first take: worse-than-expected GPM pressure |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
